CLX

Business profile & competitive position

The Clorox Company is a Consumer Defensive name in the Household & Personal Products industry. It manufactures and markets consumer and professional products under a stable of familiar brands — Clorox, Pine-Sol, Glad, Fresh Step, Kingsford, Hidden Valley, Brita, and Burt's Bees on the consumer side, plus Purell, CloroxPro, and CloroxHealthcare on the professional side. According to its most recent 10-K, the company generated fiscal 2026 net sales of $6.7 billion, employed about 9,200 people, operated in roughly 25 countries, and sold into approximately 95 markets. Scale and shelf presence are real, but the numbers also show a business whose economics are more mixed than the brand recognition suggests.

The company's net margin is 8.7%. That is a positive, profitable consumer-staples-type figure, but it is not especially wide — it implies pricing power that is solid yet constrained by retailer concentration and competitive private-label alternatives. More striking is the reported return on equity of -1,893.5%. An ROE that deeply negative almost always signals a balance-sheet phenomenon rather than an operating loss: cumulative share buybacks, dividends, and/or accumulated losses can drive shareholders' equity below zero, which mathematically blows up the ROE ratio even when net income is positive. The 8.7% net margin confirms the business is operationally profitable; the ROE flag suggests investors should look carefully at equity, leverage, and how capital has been returned or eroded over time. The beta of 0.54 fits the defensive classification — the stock historically moved much less than the broad market.

Customer concentration is another structural consideration. Walmart alone accounted for 26% of consolidated FY2026 net sales, and the five largest customers represented about half. That level of dependence on a few retailers is inherent to large household-products distribution, but it also limits negotiating flexibility and raises the stakes if any major relationship shifts.

Financial posture

Clorox currently trades at $83.3 with a market capitalization of $10.1 billion and a trailing P/E of 17.3. That valuation sits in a reasonable zone for a consumer-staples business, neither aggressively cheap nor obviously expensive on earnings alone. The 8.7% net margin provides context for the P/E: the market is paying a mid-teen multiple for mid-single-digit profitability, which is consistent with a mature, slow-growth defensive name.

The negative ROE is the loudest balance-sheet signal. With a positive net margin, the culprit is almost certainly a negative or near-zero equity base. This can happen when a company returns large amounts of cash to shareholders through buybacks and dividends while also absorbing write-downs or cumulative losses. It does not by itself indicate insolvency, but it does mean traditional ROE-based compa-rables are distorted and that debt levels deserve attention. The low 0.54 beta confirms the stock has behaved defensively, though it also tells us little about the company's underlying leverage on its own balance sheet.

Technically, the stock is currently below its 50-day EMA of $95.69 and carries an RSI of 23.4, which puts it in technically oversold territory as of the snapshot date. That price action is consistent with the FY2026 earnings decline of 26% in diluted EPS and the broader macro and ERP-transition headwinds the company cited.

Strategic priorities & outlook

The company's own 10-K outlines a clear set of near-term priorities. The umbrella framework is the IGNITE strategy, built around four choices: fueling long-term profitable growth, innovating consumer experiences, reimagining how the company and its people work, and continuously evolving the product portfolio. These are broad themes, but the filing ties them to specific operational workstreams.

The first is a major enterprise resource planning (ERP) system and digital transformation. Clorox is trying to generate long-term efficiencies across supply chain, digital commerce, innovation, and brand building. The 10-K explicitly notes that ERP transition timing pulled some sales into fiscal 2025 and contributed to FY2026's weaker organic sales and earnings, with diluted EPS down 26%. ERP rollouts are typically multi-year margin stories; near-term disruption is common, and the payoff depends on execution.

The second focus is brand investment and portfolio optimization. Clorox says it is investing in strong brands, strategic digital capabilities, and a streamlined operating model to build a more resilient company and deliver consistent, profitable growth. Separately, the Glad bags and wraps venture with P&G expired on January 31, 2026, requiring Clorox to purchase P&G's 20% interest; Glad retained core intellectual property licenses on a royalty-free basis.

The third priority is health and hygiene expansion, highlighted by the April 2026 completion of the GOJO Industries acquisition. GOJO adds Purell and expands Clorox's business-to-business and professional footprint. Integrating that acquisition and growing professional and institutional markets now sit alongside the consumer brands as explicit goals.

Macro & geopolitical exposure

As a Household & Personal Products company, Clorox is exposed to the raw-material and supply-chain realities of packaged consumer goods. Resins and chemicals for cleaning and packaging, pulp and paper for Burt's Bees and wipes, and agricultural inputs for Kingsford charcoal and Hidden Valley dressings all feed into cost of goods. Freight, warehousing, and label regulations add additional operating variables.

The sector also faces persistent regulatory exposure: EPA registration for disinfectants, FDA and FTC oversight of health claims, and state-level product-safety rules can affect formulation, labeling, and speed to market. Currency translation matters for a company selling in about 95 markets, and tariff or trade-policy changes can hit imported raw materials, components, or finished goods. On the demand side, consumer staples are defensive in downturns, but shoppers still trade down to private-label alternatives during periods of stretched household budgets, which pressures pricing and volume simultaneously.

Recent developments

Recent headlines have centered on portfolio positioning and institutional fund flows. On September 21, 2026, 247wallst.com published "Clorox vs. Kimberly-Clark: Which Household Staples Dividend Is Safer," placing Clorox in a defensive-dividend comparison with a peer. The same day, defenseworld.net reported that MAC Alpha Capital Management LP bought shares of Clorox. Two days earlier, on September 19, 2026, 247wallst.com ran "These 6 Massive Dividend Yields May Be Too Good to Be True," which included Clorox in a discussion of high-yielding staples names. On September 18, 2026, defenseworld.net noted that Baird Financial Group Inc. cut its position in the company. There is no strong consensus direction in these items — one new buyer, one seller, and two articles debating dividend safety — but together they illustrate the current market conversation: yield and balance-sheet risk in a staples name that has moved lower.

Earnings behavior & post-earnings drift

Clorox has a solid headline beat record over the last eight reported quarters: 6 beats out of 8, or 75%, with an average earnings surprise of 9.6%. The average 5-day price move after earnings across those quarters has been 1.67% to the upside, classified as an "up" drift. That said, recent individual quarters show significant volatility, so the averages hide a wide dispersion.

In the most recent report on August 3, 2026, Clorox earned $1.66 versus a $1.64 estimate (a 1.2% surprise), and the stock rose 6.52% the next day and 9.61% over the following five days. The quarter before, on April 30, 2026, the company beat by 5.8% ($1.64 vs. $1.55), yet the stock fell 9.67% the next day and was down 4.49% over five days — a reminder that beats do not guarantee positive price reactions. The February 3, 2026 report was a 2.8% miss ($1.39 vs. $1.43), but the stock still rose 2.43% the next day and 5.63% over five sessions. The November 3, 2025 quarter saw a 3.9% beat ($0.85 vs. $0.818), with the stock up 1.17% the next day but down 4.08% over five days.

The next scheduled report is November 3, 2026, after the market close, with the unofficial consensus at $1.11 EPS. The current RSI of 23.4 and the price sitting well under the 50-day EMA suggest the stock has already sold off heading into the print, which can set up a wide range of outcomes depending on guidance and any update on the GOJO integration, ERP progress, and volume trends.

For a deeper dive into how institutional analysts are currently weighing Clorox's negative equity base, ERP rollout, GOJO integration, and dividend sustainability, look at the full institutional verdict on the stock rather than relying on headline multiples alone.